According to the results of a multicenter clinical trial, a completely noninvasive procedure using high-intensity ultrasound waves to heat and destroy uterine fibroid tissue significantly relieves fibroid-related symptoms in women. The study results were presented at the annual meeting of the Radiological Society of North America.
Magnetic resonance-guided, focused ultrasound surgery (MRgFUS) allows radiologists to target fibroids without harming healthy surrounding tissue. "This treatment immediately stops blood flow in the fibroid tissue, which results in a significant, sustained decrease in symptoms for up to 12 months,"said Fiona M. Fennessy, MD, PhD, the study's lead author and instructor of radiology at Harvard Medical School.
Dr. Fennessy and her team studied 160 women with symptomatic fibroids at 5 different medical centers. The women received pretreatment MR imaging to identify and define the target fibroids for MRgFUS. The findings showed significant symptom relief at 3 and 6 months, and relief was sustained for 12 months. No serious adverse effects were reported.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs